dimethylcarbamic acid 4-[1-methylamino-3-(4-nitrophenoxy)propyl]phenyl ester | 578730-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethylcarbamic acid 4-[1-methylamino-3-(4-nitrophenoxy)propyl]phenyl ester
• 英文别名: Vgw84dju4D；[4-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl] N,N-dimethylcarbamate
• CAS: 578730-21-9
• 化学式: C₁₉H₂₃N₃O₅
• 分子量: 373.409
• InChiKey: BGGBDKDNDXWHQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  96.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  dimethylcarbamic acid 4-[1-methylamino-3-(4-nitrophenoxy)propyl]phenyl ester 在 甲酸 作用下， 以 水 、 丙酮 为溶剂， 反应 4.0h， 生成 [1-(4-dimethylcarbamoyloxyphenyl)-3-(4-nitrophenoxy)propyl]trimethylammonium iodide
  参考文献：
  名称：

  Toda, Narihiro; Tago, Keiko; Marumoto, Shinji, Bioorganic and medicinal chemistry, 2003, vol. 11, # 9, p. 1936 - 1956

  摘要：

  DOI：
• 作为产物：
  描述：

  t-butyl N-[1-[(4-dimethylcarbamoyloxy)phenyl]-3-(4-nitrophenoxy)propyl]-N-methylcarbamate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 12.0h， 生成 dimethylcarbamic acid 4-[1-methylamino-3-(4-nitrophenoxy)propyl]phenyl ester
  参考文献：
  名称：

  Toda, Narihiro; Tago, Keiko; Marumoto, Shinji, Bioorganic and medicinal chemistry, 2003, vol. 11, # 9, p. 1936 - 1956

  摘要：

  DOI：

文献信息

• Combinations
  申请人：Field John Mark

  公开号：US20050065176A1

  公开（公告）日：2005-03-24

  The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred ACHE inhibitors are donepezil (Aricept®), tacrine (cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil.

  该瞬时发明涉及一种α-2-δ配体和AChE抑制剂的组合，用于治疗，特别是用于治疗疼痛，特别是神经病性疼痛的治疗。特别偏爱的α-2-δ配体是加巴喷丁和普雷加巴林。特别偏爱的ACHE抑制剂包括多奈哌齐（阿力普特®）、他克林（可格林®）、利伐司特（埃克洛尔®）、生理毒素（斯纳普通®）、加兰他明（瑞莫灵）、美曲磷（普罗美）、新斯的明（普罗斯的明）和伊科唑。
• Benzylamine analogues
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040067981A1

  公开（公告）日：2004-04-08

  A compound of the formula (I): 1 wherein R 1 represents C 1 -C 6 alkyl, amino (C 1 -C 6 alkyl)amino, di(C 1 -C 6 alkyl) amino or a nitrogen-containing saturated heterocyclic; R 2 and R 3 are the same or different and represent hydrogen or C 1 -C 6 alkyl; R a represents C 1 -C 6 alkyl or C 2 -C 6 alkenyl or together with R 2 represents a C 1 -C 3 alkylene; Arom represents aryl or heteroaryl; A represents a C 1 -C 6 alkylene; E represents a single bond, oxygen, sulfur or R 4 NR 4 —, wherein R 4 is hydrogen or C 1 -C 7 alkenoyl; X 1 and X 2 are the same or different and represent oxygen or sulfur; or a pharmacologically acceptable salt or ester thereof. The compound has superior acetylcholinesterase inhibitory action and selective serotonin reuptake inhibitory action, and is useful for treating or preventing Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders.

  化合物的化学式为（I）：1，其中R1代表C1-C6烷基，氨基（C1-C6烷基）氨基，二（C1-C6烷基）氨基或含氮饱和杂环；R2和R3相同或不同，代表氢或C1-C6烷基；R代表C1-C6烷基或C2-C6烯基或与R2一起代表C1-C3烷基；Arom代表芳基或杂芳基；A代表C1-C6烷基；E代表单键，氧，硫或R4NR4—，其中R4为氢或C1-C7烯酰基；X1和X2相同或不同，代表氧或硫；或其药学上可接受的盐或酯。该化合物具有优异的乙酰胆碱酯酶抑制作用和选择性5-羟色胺再摄取抑制作用，并可用于治疗或预防阿尔茨海默病、抑郁症、亨廷顿舞蹈症、皮克病、迟发性运动障碍、强迫性障碍或惊恐障碍。
• BENZYLAMINE ANALOGUE
  申请人：BTG INTERNATIONAL LIMITED

  公开号：EP1362844B1

  公开（公告）日：2007-12-05
• Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
  申请人：Gallagher Michela

  公开号：US20050267077A1

  公开（公告）日：2005-12-01

  The present invention provides methods and compositions for improving cognitive function by administering a GABA B receptor antagonist and an acetylcholinesterase inhibitor.
• METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：Gallagher Michela

  公开号：US20110212928A1

  公开（公告）日：2011-09-01

  The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.